IJU Case Reports最新文献_第7页

Editorial Comment to Varicocelectomy Restores Spermatogenesis in Fontan-Associated Varicocele: A Two-Case Series. 精索静脉曲张切除术恢复fontan相关性精索静脉曲张的精子生成：一个两例系列。

IF 0.5

IJU Case Reports Pub Date : 2026-07-14 eCollection Date: 2026-07-01 DOI: 10.1002/iju5.70230

Teppei Takeshima

引用次数: 0

Selective Tumor-to-Tumor Metastasis of the LCNEC Component of a Combined Lung Carcinoma to Clear Cell Renal Cell Carcinoma Despite a Concurrent Meningioma. 合并肺癌到透明细胞肾细胞癌的LCNEC成分的选择性肿瘤间转移，尽管并发脑膜瘤。

IF 0.5

IJU Case Reports Pub Date : 2026-07-13 eCollection Date: 2026-07-01 DOI: 10.1002/iju5.70225

Nakanori Fujii, Yoshinobu Hoshii, Koichiro Hiyoshi, Takanori Tokunaga, Kosuke Shimizu, Keita Kobayashi, Hiroshi Hirata, Koji Shiraishi

{"title":"Selective Tumor-to-Tumor Metastasis of the LCNEC Component of a Combined Lung Carcinoma to Clear Cell Renal Cell Carcinoma Despite a Concurrent Meningioma.","authors":"Nakanori Fujii, Yoshinobu Hoshii, Koichiro Hiyoshi, Takanori Tokunaga, Kosuke Shimizu, Keita Kobayashi, Hiroshi Hirata, Koji Shiraishi","doi":"10.1002/iju5.70225","DOIUrl":"10.1002/iju5.70225","url":null,"abstract":"Introduction: Tumor-to-tumor metastasis is a rare pathological phenomenon. We report an extremely rare case in which the large cell neuroendocrine carcinoma (LCNEC) component of a combined lung carcinoma selectively metastasized to clear cell renal cell carcinoma (RCC) despite the presence of a concurrent meningioma.Case presentation: A 65-year-old man with recurrent meningioma was incidentally found to have a right lung nodule and a left renal mass. The lung tumor was diagnosed as combined LCNEC and adenocarcinoma. Partial nephrectomy revealed clear cell RCC containing a discrete metastatic focus. Hematoxylin and eosin staining showed no definitive adenocarcinoma features, whereas immunohistochemistry demonstrated CD56 and synaptophysin positivity, strongly suggesting metastasis from the LCNEC component.Conclusion: This highly selective tumor-to-tumor metastasis pattern is extremely rare, and to our knowledge, this is the first report describing selective LCNEC metastasis to RCC while sparing a synchronous meningioma.","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"9 4","pages":"e70225"},"PeriodicalIF":0.5,"publicationDate":"2026-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13364402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148438820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful Treatment of Primary Mediastinal Seminoma With Radiotherapy Following Chemotherapy Under a Bloodless Treatment Policy Based on Patient's Religious Sentiments. 基于患者宗教情感的不流血治疗策略下化疗后放疗成功治疗原发性纵隔精原细胞瘤。

IF 0.5

IJU Case Reports Pub Date : 2026-07-13 eCollection Date: 2026-07-01 DOI: 10.1002/iju5.70215

Eisuke Fujii, Yoshiyuki Yamamoto, Kentaro Takezawa, Koji Hatano, Yoichi Kakuta, Atsunari Kawashima, Norio Nonomura, Taigo Kato

{"title":"Successful Treatment of Primary Mediastinal Seminoma With Radiotherapy Following Chemotherapy Under a Bloodless Treatment Policy Based on Patient's Religious Sentiments.","authors":"Eisuke Fujii, Yoshiyuki Yamamoto, Kentaro Takezawa, Koji Hatano, Yoichi Kakuta, Atsunari Kawashima, Norio Nonomura, Taigo Kato","doi":"10.1002/iju5.70215","DOIUrl":"10.1002/iju5.70215","url":null,"abstract":"Introduction: Primary mediastinal seminoma is rare with a favorable prognosis when appropriately treated, and surgical resection after chemotherapy is the standard treatment. However, refusal of blood transfusion for religious reasons can limit curative surgical management.Case presentation: A 47-year-old Jehovah's Witness man was found to have a 10.8-cm anterior mediastinal tumor. Biopsy confirmed seminoma. As the patient refused transfusion, definitive chemotherapy followed by radiotherapy was selected. Three cycles of chemotherapy (etoposide, ifosfamide, and cisplatin) resulted in 44% tumor reduction and partial response. Intensity-modulated radiotherapy of the residual tumor (36 Gy in 20 fractions) achieved complete response, maintained for 11 months without recurrence or late toxicity.Conclusion: Sequential chemotherapy followed by consolidative radiotherapy appeared to be a safe and effective option for primary mediastinal germ cell tumor in the short term when surgical resection was not feasible for religious reasons.","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"9 4","pages":"e70215"},"PeriodicalIF":0.5,"publicationDate":"2026-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13364509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148450344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Meaningful Radiographic and Metabolic Response to Enzalutamide Plus Radium-223 Therapy in Metastatic Castration-Resistant Prostate Cancer With PSA-Discordant Progression: A Case Report. 恩杂鲁胺加镭-223治疗转移性去势抵抗性前列腺癌伴psa不一致进展的有意义的放射学和代谢反应：1例报告。

IF 0.5

IJU Case Reports Pub Date : 2026-07-13 eCollection Date: 2026-07-01 DOI: 10.1002/iju5.70224

Yamato Numata, Go Kimura, Jun Akatsuka, Hikaru Mikami, Kotaro Obayashi, Yuki Endo, Hayato Takeda, Yuka Toyama, Ryuji Ohashi, Yukihiro Kondo

{"title":"Meaningful Radiographic and Metabolic Response to Enzalutamide Plus Radium-223 Therapy in Metastatic Castration-Resistant Prostate Cancer With PSA-Discordant Progression: A Case Report.","authors":"Yamato Numata, Go Kimura, Jun Akatsuka, Hikaru Mikami, Kotaro Obayashi, Yuki Endo, Hayato Takeda, Yuka Toyama, Ryuji Ohashi, Yukihiro Kondo","doi":"10.1002/iju5.70224","DOIUrl":"10.1002/iju5.70224","url":null,"abstract":"Introduction: The combination of enzalutamide and radium-223 has demonstrated clinical efficacy in metastatic castration-resistant prostate cancer; however, real-world evidence remains limited, particularly with PSA-discordant progression.Case presentation: A 74-year-old man with high-risk localized prostate cancer was treated with androgen deprivation therapy followed by definitive external beam radiotherapy. Eight months later, the disease progressed radiographically with extensive bone, nodal, and solitary liver metastases, while prostate-specific antigen levels remained persistently low, consistent with prostate-specific antigen-discordant progression. Bone turnover markers and disease activity markers were markedly elevated. Combination therapy with enzalutamide and radium-223 was initiated, and six cycles of radium-223 were completed. Following treatment, skeletal disease activity and bone turnover markers improved markedly. Apart from grade 3 anemia requiring transfusion, no severe adverse events occurred.Conclusion: This case suggests that enzalutamide combined with radium-223 may provide clinical benefit in metastatic castration-resistant prostate cancer with PSA-discordant progression.","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"9 4","pages":"e70224"},"PeriodicalIF":0.5,"publicationDate":"2026-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13364506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148450361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Hybrid Retroperitoneal-Transperitoneal Approach for Robot-Assisted Radical Nephrectomy: A Technical Report of Two Cases. 腹膜后-经腹膜混合入路用于机器人辅助根治性肾切除术：附2例技术报告。

IF 0.5

IJU Case Reports Pub Date : 2026-07-12 eCollection Date: 2026-07-01 DOI: 10.1002/iju5.70226

Takayuki Ohzeki, Yuto Mitsuhashi, Lan Inoki, Tsuyoshi Morita, Taiji Hayashi, Tsukasa Nishioka, Saizo Fujimoto, Kazutoshi Fujita

引用次数: 0

A Rare Case of Suspected Immune-Related Encephalopathy Following Pembrolizumab Plus Lenvatinib Therapy for Renal Cell Carcinoma. 肾细胞癌派姆单抗加Lenvatinib治疗后疑似免疫相关性脑病的罕见病例

IF 0.5

IJU Case Reports Pub Date : 2026-07-12 eCollection Date: 2026-07-01 DOI: 10.1002/iju5.70227

Yuina Nagao, Kyotaro Fukuta, Yuichiro Atagi, Keisuke Ozaki, Takeshi Nakashima, Kenta Sato, Ryoichi Nakanishi, Hirofumi Izaki, Junya Furukawa

{"title":"A Rare Case of Suspected Immune-Related Encephalopathy Following Pembrolizumab Plus Lenvatinib Therapy for Renal Cell Carcinoma.","authors":"Yuina Nagao, Kyotaro Fukuta, Yuichiro Atagi, Keisuke Ozaki, Takeshi Nakashima, Kenta Sato, Ryoichi Nakanishi, Hirofumi Izaki, Junya Furukawa","doi":"10.1002/iju5.70227","DOIUrl":"10.1002/iju5.70227","url":null,"abstract":"Introduction: Immune-related encephalopathy is a rare neurological adverse event associated with immune checkpoint inhibitors. Neuroimaging and cerebrospinal fluid findings are often unremarkable, making the diagnosis challenging.Case presentation: A 70-year-old man with advanced clear cell renal cell carcinoma (RCC) was considered unresectable because of suspected adjacent organ invasion and high surgical risk. Therefore, pembrolizumab plus lenvatinib therapy was initiated, but 6 days later, he developed confusion, speech difficulty, and gait disturbance. Blood tests, whole-body computed tomography (CT), contrast-enhanced brain CT, contrast-enhanced brain magnetic resonance imaging (MRI), electroencephalography, and cerebrospinal fluid examination showed no significant abnormalities. After excluding other causes, grade 3 immune-related encephalopathy was suspected. Pembrolizumab and Lenvatinib were discontinued and high-dose corticosteroids were started, leading to subsequent neurological improvement without residual deficits.Conclusion: Immune-related encephalopathy may occur early after pembrolizumab therapy. Early recognition and prompt steroid treatment are essential for a favorable neurological recovery.","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"9 4","pages":"e70227"},"PeriodicalIF":0.5,"publicationDate":"2026-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13358212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148438873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metastatic Testicular Germ Cell Tumor in a Patient With Neurofibromatosis Type 1: Treatment With Trametinib Based on NF1 Gene Mutation. 1型神经纤维瘤患者的转移性睾丸生殖细胞瘤：基于NF1基因突变的曲美替尼治疗

IF 0.5

IJU Case Reports Pub Date : 2026-07-09 eCollection Date: 2026-07-01 DOI: 10.1002/iju5.70223

Keita Goto, Toshiki Kijima, Yusuke Sato, Kousuke Watanabe, Hidenori Kage, Katsutoshi Oda, Tatsunori Shimoi, Kazuyuki Ishida, Haruki Kume, Takao Kamai

{"title":"Metastatic Testicular Germ Cell Tumor in a Patient With Neurofibromatosis Type 1: Treatment With Trametinib Based on NF1 Gene Mutation.","authors":"Keita Goto, Toshiki Kijima, Yusuke Sato, Kousuke Watanabe, Hidenori Kage, Katsutoshi Oda, Tatsunori Shimoi, Kazuyuki Ishida, Haruki Kume, Takao Kamai","doi":"10.1002/iju5.70223","DOIUrl":"10.1002/iju5.70223","url":null,"abstract":"Introduction: Neurofibromatosis type 1 (NF1) is a genetic disorder that increases the risk of various tumors. However, its association with testicular germ cell tumors (GCTs) is rare. We report a case of metastatic GCT in an NF1 patient treated with precision medicine.Case presentation: A 40-year-old male with NF1 presented with a left testicular non-seminomatous GCT and lung metastases. The tumor showed progressive disease after chemotherapy (VIP, TGP) and surgical removal of metastases. Comprehensive genomic profiling (CGP) test found a pathogenic NF1 frameshift mutation (p.Q514fs*43). Based on this finding, the patient received the MEK inhibitor trametinib under patient-proposed healthcare services (BELIEVE Trial). Treatment resulted in normalization of serum alpha-fetoprotein (AFP) for 6 months before the tumor eventually progressed. The patient died at 39 months after diagnosis.Conclusion: This is the first report of trametinib for a metastatic GCT with an NF1 mutation, suggesting a possible but limited treatment effect.Trial registration: The prospective trial of patient-proposed healthcare services with multiple targeted agents based on the results of gene profiling by multigene panel test (BELIEVE), NCCH1901/jRCTs031190104.","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"9 4","pages":"e70223"},"PeriodicalIF":0.5,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13349590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148426427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acquired Autoimmune Factor XIII Deficiency as a Novel Immune-Related Adverse Event of Combined Ipilimumab and Nivolumab Therapy for Renal Cell Carcinoma: A Case Report. 获得性自身免疫因子XIII缺乏作为伊匹单抗和纳武单抗联合治疗肾细胞癌的一种新的免疫相关不良事件：一例报告

IF 0.5

IJU Case Reports Pub Date : 2026-07-08 eCollection Date: 2026-07-01 DOI: 10.1002/iju5.70207

Shigeyasu Tetsushi, Koura Mikifumi, Ootsubo Satoshi, Hasegawa Shuji, Tatsugami Katsunori

{"title":"Acquired Autoimmune Factor XIII Deficiency as a Novel Immune-Related Adverse Event of Combined Ipilimumab and Nivolumab Therapy for Renal Cell Carcinoma: A Case Report.","authors":"Shigeyasu Tetsushi, Koura Mikifumi, Ootsubo Satoshi, Hasegawa Shuji, Tatsugami Katsunori","doi":"10.1002/iju5.70207","DOIUrl":"10.1002/iju5.70207","url":null,"abstract":"Introduction: Combination therapy with immune checkpoint inhibitors (ICIs) has become the standard pharmacological treatment for renal cell carcinoma; however, careful attention must be paid to immune-related adverse events (irAEs). We report a rare case of acquired autoimmune factor XIII deficiency following ipilimumab plus nivolumab therapy.Case presentation: A 75-year-old woman who had previously undergone nephrectomy for left renal cell carcinoma developed pancreatic and pulmonary metastases and was started on combination immunotherapy. Six months after treatment initiation, she presented with bleeding symptoms. Laboratory testing revealed anti-factor XIII autoantibodies, confirming a diagnosis of acquired autoimmune factor XIII deficiency.Conclusion: To our knowledge, few reports have described this condition as an irAE. Nonetheless, other irAE-related acquired coagulation factor deficiencies-such as factor V deficiency and acquired hemophilia A-have been reported. These precedents suggest a high likelihood that the current case represents a novel manifestation of irAE.","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"9 4","pages":"e70207"},"PeriodicalIF":0.5,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13345983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148426461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Case of Bladder Paraganglioma With Negative Photodynamic Diagnosis Completely Resected by Staged En Bloc Transurethral Resection. 经尿道分阶段整体切除膀胱副神经节瘤1例。

IF 0.5

IJU Case Reports Pub Date : 2026-07-03 eCollection Date: 2026-07-01 DOI: 10.1002/iju5.70220

Shu Gozu, Yasukazu Nakanishi, Gaku Okumura, Erika Ikezoe, Naoki Imasato, Kohei Hirose, Madoka Kataoka, Shugo Yajima, Hitoshi Masuda

{"title":"A Case of Bladder Paraganglioma With Negative Photodynamic Diagnosis Completely Resected by Staged En Bloc Transurethral Resection.","authors":"Shu Gozu, Yasukazu Nakanishi, Gaku Okumura, Erika Ikezoe, Naoki Imasato, Kohei Hirose, Madoka Kataoka, Shugo Yajima, Hitoshi Masuda","doi":"10.1002/iju5.70220","DOIUrl":"10.1002/iju5.70220","url":null,"abstract":"Introduction: Bladder paraganglioma can be challenging to distinguish from nonpapillary bladder cancer. Here, we report a case of nonfunctional bladder paraganglioma treated with photodynamic diagnosis-assisted en bloc transurethral resection of the bladder tumor.Case presentation: A 78-year-old man was incidentally diagnosed with a bladder tumor on imaging. Radiological and cystoscopic findings suggested bladder paraganglioma or nonpapillary urothelial carcinoma. The patient underwent en bloc transurethral resection of the bladder tumor with photodynamic diagnosis using 5-aminolevulinic acid. No fluorescence enhancement was observed during photodynamic diagnosis. Histopathological examination revealed nonfunctional bladder paraganglioma. A second-look en bloc transurethral resection with photodynamic diagnosis confirmed the absence of a residual tumor.Conclusion: This case highlights the diagnostic pitfalls of nonfunctional bladder paraganglioma presenting as a photodynamic diagnosis-negative bladder tumor and suggests that en bloc transurethral resection may be an effective organ-preserving approach in selected cases.","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"9 4","pages":"e70220"},"PeriodicalIF":0.5,"publicationDate":"2026-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13331875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148392442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Two Cases of Bilateral Ureteral Metastases From Prostate Cancer Initially Presenting With Postrenal Acute Kidney Injury 双侧前列腺癌输尿管转移最初表现为肾后急性肾损伤2例。

IF 0.5

IJU Case Reports Pub Date : 2026-07-01 DOI: 10.1002/iju5.70222

Hiroshi Ushida, Ryo Ikari, Hiromu Tokuchi, Yumi Manabe

{"title":"Two Cases of Bilateral Ureteral Metastases From Prostate Cancer Initially Presenting With Postrenal Acute Kidney Injury","authors":"Hiroshi Ushida, Ryo Ikari, Hiromu Tokuchi, Yumi Manabe","doi":"10.1002/iju5.70222","DOIUrl":"10.1002/iju5.70222","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 Although prostate-specific antigen (PSA) screening has facilitated early detection of prostate cancer, approximately 5% of patients still present with distant metastases at diagnosis. Ureteral metastasis from prostate cancer is extremely rare.\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 We report two cases of clinically diagnosed bilateral ureteral metastases in which postrenal acute kidney injury caused by bilateral hydronephrosis preceded the diagnosis of prostate cancer. Histopathological confirmation by ureteroscopic biopsy was not possible in either case. However, marked improvement in ureteral obstruction following initiation of androgen deprivation therapy supported the diagnosis.\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 Bilateral ureteral metastases from prostate cancer may present with acute kidney injury, and therapeutic response to androgen deprivation therapy may provide an important diagnostic clue when pathological confirmation is difficult.\u0000 </section>\u0000 </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"9 4","pages":""},"PeriodicalIF":0.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13320363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148370869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0